BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia

Cancer Cell

Volumn 26, Issue 3, 2014, Pages 428-442

  Zabriskie, Matthew S ^a   Eide, Christopher A ^b,c   Tantravahi, Srinivas K ^a,d   Vellore, Nadeem A ^e   Estrada, Johanna ^a   Nicolini, Franck E ^f   Khoury, Hanna J ^g   Larson, Richard A ^h   Konopleva, Marina ⁱ   Cortes, Jorge E ⁱ   Kantarjian, Hagop ⁱ   Jabbour, Elias J ⁱ   Kornblau, Steven M ⁱ   Lipton, Jeffrey H ^j   Rea, Delphine ^k   Stenke, Leif ^l   Barbany, Gisela ^l   Lange, Thoralf ^m   Hernández Boluda, Juan Carlos ⁿ   Ossenkoppele, Gert J ^o   Press, Richard D ^p   Chuah, Charles ^q   Goldberg, Stuart L ^r   Wetzler, Meir ^s   Mahon, Francois Xavier ^t   Etienne, Gabriel ^u   Baccarani, Michele ^v   Soverini, Simona ^v   Rosti, Gianantonio ^v   Rousselot, Philippe ^w   Friedman, Ran ^x   Deininger, Marie ^a   Reynolds, Kimberly R ^a   Heaton, William L ^a   Eiring, Anna M ^a   Pomicter, Anthony D ^a   Khorashad, Jamshid S ^a   Kelley, Todd W ^y   Baron, Riccardo ^e   Druker, Brian J ^b,c   Deininger, Michael W ^a,d   O'Hare, Thomas ^a,d   more..

^a UNIVERSITY OF UTAH   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^d UNIVERSITY OF UTAH   (United States)

^e UNIVERSITY OF UTAH   (United States)

^f CENTRE DE RECHERCHE EN CANCÉROLOGIE DE LYON   (France)

^g EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF CHICAGO   (United States)

ⁱ UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^j UNIVERSITY OF TORONTO   (Canada)

^k SAINT LOUIS HOSPITAL   (France)

^l KAROLINSKA INSTITUTE   (Sweden)

^m UNIVERSITY OF LEIPZIG   (Germany)

ⁿ HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^o VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^p OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^q SINGAPORE GENERAL HOSPITAL   (Singapore)

^r HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

^s ROSWELL PARK CANCER INSTITUTE   (United States)

^t BORDEAUX UNIVERSITY HOSPITAL   (France)

^u INSTITUT BERGONIÉ   (France)

^v UNIVERSITY OF BOLOGNA   (Italy)

^w LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^x LINNAEUS UNIVERSITY   (Sweden)

^y UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; BOSUTINIB; DASATINIB; IMATINIB; NILOTINIB; PONATINIB; REBASTINIB; ANTINEOPLASTIC AGENT; IMIDAZOLE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIDAZINE DERIVATIVE;

ARTICLE; CANCER RESISTANCE; CELL PROLIFERATION; CLONAL VARIATION; GENE MUTATION; HUMAN; LEUKEMIA; MOLECULAR DOCKING; MOLECULAR DYNAMICS; PHILADELPHIA CHROMOSOME POSITIVE CELL; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; CHEMISTRY; CHRONIC MYELOID LEUKEMIA; DRUG RESISTANCE; ENZYME ACTIVE SITE; GENETICS; MISSENSE MUTATION; PHILADELPHIA 1 CHROMOSOME; PROTEIN BINDING; TREATMENT FAILURE;

ANTINEOPLASTIC AGENTS; CATALYTIC DOMAIN; DRUG RESISTANCE, NEOPLASM; FUSION PROTEINS, BCR-ABL; HUMANS; IMIDAZOLES; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MOLECULAR DYNAMICS SIMULATION; MUTATION, MISSENSE; PHILADELPHIA CHROMOSOME; PROTEIN BINDING; PROTEIN KINASE INHIBITORS; PYRIDAZINES; TREATMENT FAILURE;

EID: 84908364892     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccr.2014.07.006     Document Type: Article

References (47)

1. Apperley J.F. Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol. 2007, 8:1018-1029.
2. Awad M.M., Katayama R., McTigue M., Liu W., Deng Y.L., Brooun A., Friboulet L., Huang D., Falk M.D., Timofeevski S., et al. Acquired resistance to crizotinib from a mutation in CD74-ROS1. N. Engl. J. Med. 2013, 368:2395-2401.
3. Azam M., Latek R.R., Daley G.Q. Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell 2003, 112:831-843.
4. Azam M., Seeliger M.A., Gray N.S., Kuriyan J., Daley G.Q. Activation of tyrosine kinases by mutation of the gatekeeper threonine. Nat. Struct. Mol. Biol. 2008, 15:1109-1118.
5. Bradeen H.A., Eide C.A., O'Hare T., Johnson K.J., Willis S.G., Lee F.Y., Druker B.J., Deininger M.W. Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations. Blood 2006, 108:2332-2338.
6. Burgess M.R., Skaggs B.J., Shah N.P., Lee F.Y., Sawyers C.L. Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance. Proc. Natl. Acad. Sci. USA 2005, 102:3395-3400.
7. Chan W.W., Wise S.C., Kaufman M.D., Ahn Y.M., Ensinger C.L., Haack T., Hood M.M., Jones J., Lord J.W., Lu W.P., et al. Conformational control inhibition of the BCR-ABL1 tyrosine kinase, including the gatekeeper T315I mutant, by the switch-control inhibitor DCC-2036. Cancer Cell 2011, 19:556-568.
8. Corbin A.S., Buchdunger E., Pascal F., Druker B.J. Analysis of the structural basis of specificity of inhibition of the Abl kinase by STI571. J. Biol. Chem. 2002, 277:32214-32219.
9. Cortes J.E., Kantarjian H.M., Brümmendorf T.H., Kim D.W., Turkina A.G., Shen Z.X., Pasquini R., Khoury H.J., Arkin S., Volkert A., et al. Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. Blood 2011, 118:4567-4576.
10. Cortes J.E., Kantarjian H., Shah N.P., Bixby D., Mauro M.J., Flinn I., O'Hare T., Hu S., Narasimhan N.I., Rivera V.M., et al. Ponatinib in refractory Philadelphia chromosome-positive leukemias. N. Engl. J. Med. 2012, 367:2075-2088.
11. Cortes J.E., Kim D.W., Pinilla-Ibarz J., le Coutre P., Paquette R., Chuah C., Nicolini F.E., Apperley J.F., Khoury H.J., Talpaz M., et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N. Engl. J. Med. 2013, 369:1783-1796. PACE Investigators.
12. Dai Y., Rahmani M., Corey S.J., Dent P., Grant S. A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2. J. Biol. Chem. 2004, 279:34227-34239.
13. Davare M.A., Saborowski A., Eide C.A., Tognon C., Smith R.L., Elferich J., Agarwal A., Tyner J.W., Shinde U.P., Lowe S.W., Druker B.J. Foretinib is a potent inhibitor of oncogenic ROS1 fusion proteins. Proc. Natl. Acad. Sci. USA 2013, 110:19519-19524.
14. Donato N.J., Wu J.Y., Stapley J., Gallick G., Lin H., Arlinghaus R., Talpaz M. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 2003, 101:690-698.
15. Druker B.J., Guilhot F., O'Brien S.G., Gathmann I., Kantarjian H., Gattermann N., Deininger M.W., Silver R.T., Goldman J.M., Stone R.M., et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N. Engl. J. Med. 2006, 355:2408-2417. IRIS Investigators.
16. Eide C.A., Adrian L.T., Tyner J.W., Mac Partlin M., Anderson D.J., Wise S.C., Smith B.D., Petillo P.A., Flynn D.L., Deininger M.W., et al. The ABL switch control inhibitor DCC-2036 is active against the chronic myeloid leukemia mutant BCR-ABLT315I and exhibits a narrow resistance profile. Cancer Res. 2011, 71:3189-3195.
17. Gibbons D.L., Pricl S., Posocco P., Laurini E., Fermeglia M., Sun H., Talpaz M., Donato N., Quintás-Cardama A. Molecular dynamics reveal BCR-ABL1 polymutants as a unique mechanism of resistance to PAN-BCR-ABL1 kinase inhibitor therapy. Proc. Natl. Acad. Sci. USA 2014, 111:3550-3555.
18. Gorre M.E., Mohammed M., Ellwood K., Hsu N., Paquette R., Rao P.N., Sawyers C.L. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001, 293:876-880.
19. Griswold I.J., MacPartlin M., Bumm T., Goss V.L., O'Hare T., Lee K.A., Corbin A.S., Stoffregen E.P., Smith C., Johnson K., et al. Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib. Mol. Cell. Biol. 2006, 26:6082-6093.
20. Hochhaus A., Kreil S., Corbin A.S., La Rosée P., Müller M.C., Lahaye T., Hanfstein B., Schoch C., Cross N.C., Berger U., et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 2002, 16:2190-2196.
21. Hochhaus A., Saglio G., Larson R.A., Kim D.W., Etienne G., Rosti G., De Souza C., Kurokawa M., Kalaycio M.E., Hoenekopp A., et al. Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Blood 2013, 121:3703-3708.
22. Kantarjian H., Giles F., Wunderle L., Bhalla K., O'Brien S., Wassmann B., Tanaka C., Manley P., Rae P., Mietlowski W., et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N. Engl. J. Med. 2006, 354:2542-2551.
23. Kastner R., Zopf A., Preuner S., Pröll J., Niklas N., Foskett P., Valent P., Lion T., Gabriel C. Rapid identification of compound mutations in patients with Philadelphia-positive leukaemias by long-range next generation sequencing. Eur. J. Cancer 2014, 50:793-800.
24. Khorashad J.S., Anand M., Marin D., Saunders S., Al-Jabary T., Iqbal A., Margerison S., Melo J.V., Goldman J.M., Apperley J.F., Kaeda J. The presence of a BCR-ABL mutant allele in CML does not always explain clinical resistance to imatinib. Leukemia 2006, 20:658-663.
25. Khorashad J.S., Milojkovic D., Mehta P., Anand M., Ghorashian S., Reid A.G., De Melo V., Babb A., de Lavallade H., Olavarria E., et al. Invivo kinetics of kinase domain mutations in CML patients treated with dasatinib after failing imatinib. Blood 2008, 111:2378-2381.
26. Khorashad J.S., Kelley T.W., Szankasi P., Mason C.C., Soverini S., Adrian L.T., Eide C.A., Zabriskie M.S., Lange T., Estrada J.C., et al. BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships. Blood 2013, 121:489-498.
27. Kim D., Kim D.W., Cho B.S., Goh H.G., Kim S.H., Kim W.S., Lee J., Kweon I.Y., Park S.H., Yoon J.H., et al. Structural modeling of V299L and E459K Bcr-Abl mutation, and sequential therapy of tyrosine kinase inhibitors for the compound mutations. Leuk. Res. 2009, 33:1260-1265.
28. Kim W.S., Kim D., Kim D.W., Kweon I.Y., Kim S.H., Goh H.G., Park S.H., Lee J. Dynamic change of T315I BCR-ABL kinase domain mutation in Korean chronic myeloid leukaemia patients during treatment with Abl tyrosine kinase inhibitors. Hematol. Oncol. 2010, 28:82-88.
29. Manley P.W., Cowan-Jacob S.W., Mestan J. Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia. Biochim. Biophys. Acta 2005, 1754:3-13.
30. O'Hare T., Shakespeare W.C., Zhu X., Eide C.A., Rivera V.M., Wang F., Adrian L.T., Zhou T., Huang W.S., Xu Q., et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 2009, 16:401-412.
31. O'Hare T., Zabriskie M.S., Eiring A.M., Deininger M.W. Pushing the limits of targeted therapy in chronic myeloid leukaemia. Nat. Rev. Cancer 2012, 12:513-526.
32. Peng B., Hayes M., Resta D., Racine-Poon A., Druker B.J., Talpaz M., Sawyers C.L., Rosamilia M., Ford J., Lloyd P., Capdeville R. Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. J. Clin. Oncol. 2004, 22:935-942.
33. Ray A., Cowan-Jacob S.W., Manley P.W., Mestan J., Griffin J.D. Identification of BCR-ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study. Blood 2007, 109:5011-5015.
34. Redaelli S., Piazza R., Rostagno R., Magistroni V., Perini P., Marega M., Gambacorti-Passerini C., Boschelli F. Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants. J. Clin. Oncol. 2009, 27:469-471.
35. Senior M. FDA halts then allows sales of Ariad's leukemia medication. Nat. Biotechnol. 2014, 32:9-11.
36. Shah N.P., Tran C., Lee F.Y., Chen P., Norris D., Sawyers C.L. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004, 305:399-401.
37. Shah N.P., Skaggs B.J., Branford S., Hughes T.P., Nicoll J.M., Paquette R.L., Sawyers C.L. Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. J. Clin. Invest. 2007, 117:2562-2569.
38. Skaggs B.J., Gorre M.E., Ryvkin A., Burgess M.R., Xie Y., Han Y., Komisopoulou E., Brown L.M., Loo J.A., Landaw E.M., et al. Phosphorylation of the ATP-binding loop directs oncogenicity of drug-resistant BCR-ABL mutants. Proc. Natl. Acad. Sci. USA 2006, 103:19466-19471.
39. Smith C.C., Lasater E.A., Zhu X., Lin K.C., Stewart W.K., Damon L.E., Salerno S., Shah N.P. Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD. Blood 2013, 121:3165-3171.
40. Soverini S., Gnani A., Colarossi S., Castagnetti F., Abruzzese E., Paolini S., Merante S., Orlandi E., de Matteis S., Gozzini A., et al. Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors. Blood 2009, 114:2168-2171.
41. Soverini S., De Benedittis C., Machova Polakova K., Brouckova A., Horner D., Iacono M., Castagnetti F., Gugliotta G., Palandri F., Papayannidis C., et al. Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain. Blood 2013, 122:1634-1648.
42. Stagno F., Stella S., Berretta S., Massimino M., Antolino A., Giustolisi R., Messina A., Di Raimondo F., Vigneri P. Sequential mutations causing resistance to both Imatinib Mesylate and Dasatinib in a chronic myeloid leukaemia patient progressing to lymphoid blast crisis. Leuk. Res. 2008, 32:673-674.
43. Talpaz M., Shah N.P., Kantarjian H., Donato N., Nicoll J., Paquette R., Cortes J., O'Brien S., Nicaise C., Bleickardt E., et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N. Engl. J. Med. 2006, 354:2531-2541.
44. Tanneeru K., Guruprasad L. Ponatinib is a pan-BCR-ABL kinase inhibitor: MD simulations and SIE study. PLoS ONE 2013, 8:e78556.
45. Tokarski J.S., Newitt J.A., Chang C.Y., Cheng J.D., Wittekind M., Kiefer S.E., Kish K., Lee F.Y., Borzillerri R., Lombardo L.J., et al. The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Res. 2006, 66:5790-5797.
46. Weisberg E., Manley P.W., Breitenstein W., Brüggen J., Cowan-Jacob S.W., Ray A., Huntly B., Fabbro D., Fendrich G., Hall-Meyers E., et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005, 7:129-141.
47. Zhou T., Commodore L., Huang W.S., Wang Y., Thomas M., Keats J., Xu Q., Rivera V.M., Shakespeare W.C., Clackson T., et al. Structural mechanism of the Pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance. Chem. Biol. Drug Des. 2011, 77:1-11.